Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Colorectal Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

December 15, 2024

Primary Completion Date

August 15, 2025

Study Completion Date

August 15, 2026

Conditions
Colorectal Cancer (CRC)
Interventions
BIOLOGICAL

IM96 CAR-T Cells

IM96 CAR-T Cells, 12×10\^8 CAR-T cells, 20×10\^8 CAR-T cells, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D- 3), determined by tumor burden at baseline. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 300 mg/ m\^2 (D-5\~D-3), determined by tumor burden at baseline.

Trial Locations (1)

100142

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors
collaborator

Peking University Cancer Hospital & Institute

OTHER

lead

Beijing Immunochina Medical Science & Technology Co., Ltd.

INDUSTRY